GaëlSaint Olive

Partner

Parigi + 33.1.56.59.39.39

Collegati

Condividi

Gaël Saint Olive advises French and foreign clients in international mergers and acquisitions and joint ventures, including multijurisdictional transactions involving coordination of legal teams in multiple countries. Gaël is ranked yearly among the best corporate/M&A lawyers in France by The Legal 500 EMEA.

He advised Sanofi in the creation of a joint venture with Lonza, the dismantlement of its European joint venture with Merck & Co. pertaining to vaccines, the sale of research sites and related research partnership and IP licenses to Evotec AG, the sale of various worldwide or multinational pharmaceutical businesses and of an African subsidiary, the acquisition of a leading generics manufacturer in Colombia, and the acquisition of pharmaceutical assets in Africa.

Other representative clients include: Solvay in the sale of one of its European divisions to Imerys; Simon Property Group in the acquisition of a 27.8% interest in Klépierre; Société de Financement Local (SFIL) in its creation as part of the market withdrawal of Dexia Crédit Local; and Caisse des Dépôts et Consignations in connection with several public-private partnerships and the High Museum in Atlanta in its partnership with Musée du Louvre.

Esperienze

  • Sanofi sells two established product portfolios to NeuraxpharmJones Day advised Sanofi in the sale of 2 portfolios of products for central nervous systems disorders and pain and vascular diseases to LESVI, a Spanish subsidiary of Neuraxpharm.
  • Lagardère Travel Retail renews JV with Groupe ADPJones Day advised Lagardère Travel Retail in the renewal of its joint venture with Aeroports de Paris including the acquisition of a 49% interest in Extime.
  • Sanofi divests IMOJEV® to SUBSTIPHARMJones Day advised Sanofi in the sale of the Japanese Encephalitis vaccine IMOJEV® to SUBSTIPHARM, a privately held pharmaceutical group.
  • Sanofi sells anti-infective portfolio to ADVANZ PHARMAJones Day advised Sanofi in the sale of a portfolio made up of eight anti-infectives including Azactam™, Cefotax™, Claforan™, Oroken™, Rulid™, Suprax™, Wintriaxone™ and Colistimethate Sodique products, which are critical in treating a broad range of infections, to ADVANZ PHARMA Corp. Limited, a UK-headquartered global pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals.
  • Sanofi announces carve-out creating EUROAPI and spin-off of approximately 58% of shares to its shareholdersJones Day advised Sanofi in the carve out creating EUROAPI (a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients) and the listing of this entity on Euronext Paris and the placement of 12% to the French State (through French Tech Souveraineté) for a price of up to €150 million.
  • Sanofi sells 10 established products to CheplapharmJones Day advised Sanofi in the sale of a portfolio of pharmaceutical products to Cheplapharm Arzneimittel GmbH, a German privately-owned company headquartered in Greifswald, Germany.
  • Sanofi divests 16 brands to STADAJones Day advised Sanofi in the sale of 16 Consumer Healthcare products commercialized in Europe to STADA Arzneimittel AG.
  • Sanofi sells portfolio of established dental care brands to SeptodontJones Day advised Sanofi in the sale of an integrated portfolio of dental care brands and related medical devices to Septodont, a French privately-owned company headquartered near Paris.
  • Sanofi sells anti-inflammatory drugs to Fidia FarmaceuticiJones Day advised Sanofi in the sale of a portfolio of pharmaceutical products to Fidia Farmaceutici.
  • Solvay sold Process Materials business to Composites OneJones Day advised Solvay S.A., a publicly listed chemical company based in Brussels, Belgium, in the sale of its Process Materials business, to Composites One, the leading North American supplier of composites materials and value added services.
  • Astellas returns rights to Eligard® in Europe, Middle East, CIS, and Asia to TolmarJones Day represented Astellas Pharma Europe Ltd. in connection with a series of transactions, including the sale of related assets, in which Astellas returned its in-licensing rights to Eligard® (leuprorelin acetate for injectable suspension), a treatment for advanced prostate cancer, sold by Astellas in Europe, the Middle East, the Commonwealth of Independent States (CIS) and Asia, to Tolmar International Limited.
  • Sanofi sold Effortil (Etilefrin) pharmaceuticals products to SERB SAJones Day advised Sanofi in the sale of the Effortil (Etilefrin) pharmaceuticals products to SERB SA.
  • Sanofi sold "Biopark by Sanofi" to Evotec SEJones Day advised Sanofi in the sale of "Biopark by Sanofi" to Evotec SE.
  • Sanofi sold Lepticur to Laboratoires DelbertJones Day advised Sanofi in the sale of Lepticur to Laboratoires Delbert.
  • Sanofi sold two product portfolios to CHEPLAPHARMJones Day advised Sanofi in the sale of a portfolio of pharmaceuticals products to CHEPLAPHARM Arzneimittel GmbH.
  • Government of the Republic of Togo privatizes telecommunications companyJones Day advised the Government of the Republic of Togo on an international bidding procedure to privatize TogoCom.
  • Sanofi sells infectious disease unit to EvotecJones Day advised Sanofi in the sale of its infectious disease unit to Evotec AG.
  • Sanofi sells over-the-counter portfolio to Charterhouse for €158 million (US$195 million)Jones Day advised Sanofi SA in its €158 million (US$195 million) sale of a portfolio of 12 over-the-counter pharmaceuticals products to an affiliate of the Cooper-Vemedia group, a subsidiary of Charterhouse Capital Partners LLP group.
  • Vivendi sells stake in Ubisoft Entertainment for approximately €2 billionJones Day advised Crédit Agricole Corporate and Investment Bank (CACIB) in connection with the sale by Vivendi of its stake in Ubisoft Entertainment (Ubisoft) for approximately €2 billion.
  • Campus Agro leads AgroParisTech-INRA campus project in SaclayJones Day advised Caisse des Depots et Consignations (CDC), as shareholder of Campus Agro SAS (a company created by AgroParisTech, INRA, and CDC), on a project including (i) a public-public partnership and (ii) a public-private partnership (€257 million) lasting for 30 years with a consortium led by GTM Bâtiment (VINCI group) and ENGIE Cofely. The consortium will design, build, maintain, and operate the new AgroParisTech-INRA campus in Saclay.
    •

    Altre Pubblicazioni

    • March 20, 2006
      Dépénalisation, vous avez dit dépénalisation ?, Option Finance

    • 12 avril 2018
      Finale de la 4ème édition du Prix Jones Day/Paris II/ESSEC
    • 20 avril 2017
      Finale de la 3ème édition du Prix Jones Day/ESSEC/Paris II
    • 24 mai 2016
      Réforme du droit des contrats et du droit des obligations - 1er volet : quel impact pour vos opérations M&A ?

    Prima di procedere all'invio, si prega di notare:

    il contenuto del presente sito web è a scopo esclusivamente informativo e non può essere considerato un parere legale o altro tipo di consulenza professionale. L'invio o la ricezione della presente email non è atta ad instaurare alcun rapporto cliente/avvocato. Le informazioni inviate tramite questa funzione al nostro Studio non saranno coperte da vincolo di riservatezza o confidenzialità fintanto che non ci sia stato conferito e non sia stato da noi accettato un incarico professionale. Inviando il messaggio confermate di aver preso visione e accettato il contenuto di questa informativa.